Maxillary Mucormycosis Osteomyelitis in Post COVID-19 Patients: A Series of Fourteen Cases

Wael M. Said Ahmed; Amira M. Elsherbini; Nehal M. Elsherbiny; Mohamed El-Sherbiny; Nevine I. Ramzy; Ahmed F. Arafa

doi:10.3390/diagnostics11112050

Diagnostics (Nov 2021)

Maxillary Mucormycosis Osteomyelitis in Post COVID-19 Patients: A Series of Fourteen Cases

Wael M. Said Ahmed,
Amira M. Elsherbini,
Nehal M. Elsherbiny,
Mohamed El-Sherbiny,
Nevine I. Ramzy,
Ahmed F. Arafa

Affiliations

Wael M. Said Ahmed: Oral and Maxillofacial Department, Faculty of Dentistry, Mansoura University, Mansoura 35516, Egypt
Amira M. Elsherbini: Oral Biology Department, Faculty of Dentistry, Mansoura University, Mansoura 35516, Egypt
Nehal M. Elsherbiny: Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt
Mohamed El-Sherbiny: Department of Basic Medical Sciences, College of Medicine, AlMaarefa University, Riyadh 71666, Saudi Arabia
Nevine I. Ramzy: Pathology Department, Faculty of Medicine, Cairo University, Giza 11562, Egypt
Ahmed F. Arafa: Oral and Maxillofacial Department, Zagazig University, Zagazig 44519, Egypt

DOI: https://doi.org/10.3390/diagnostics11112050
Journal volume & issue: Vol. 11, no. 11
p. 2050

Abstract

Read online

During the current pandemic of COVID-19, numerous manifestations and complications have developed. Patients with COVID-19 are at high risk of fungal infections, such as mucormycosis, that may result directly from COVID-19 infection and/or as a side effect of the drugs used in COVID-19 treatment protocol, such as dexamethasone, hydroxychloroquine, and antibiotics. In this report, we described a series of 14 cases with maxillary mucormycosis osteomyelitis in immediate post-COVID-19 patients.

Published in Diagnostics

ISSN: 2075-4418 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Medicine (General)
Website: http://www.mdpi.com/journal/diagnostics

About the journal

Abstract

Keywords